The role of transanal total mesorectal excision (TaTME) in the surgical treatment of rectal cancer
Abstract
Transanal total mesorectal excision (TaTME) is an innovative surgical approach for treating mid- and low-rectal cancers. The method offers several distinct advantages that make it superior to traditional techniques, with the principal benefits being better visualization and improved access to the lower pelvis. In this paper, we review the general assumptions of this method, with particular emphasis on the two-team (Cecil) approach. We also summarize our own experiences with the use of TaTME. Our experiences suggest that TaTME provides satisfactory oncological outcomes similar to those obtained with other commonly recognized surgical techniques. Moreover, TaTME is widely accepted by patients, especially those wishing to preserve their anal sphincters. However, more multicenter studies are needed to define objective indications for TaTME and to ultimately standardize the surgical technique, as published evidence suggests that many aspects of this procedure vary substantially from center to center.
Keywords: rectal cancerTaTMEsurgical technique
References
- Błaszkowski T, Celban G, Domagała M, et al. Surgical treatment of rectal cancer in Poland — a report from a prospective, multi-centre observational study PSSO_01 conducted under the auspices of the Polish Society of Surgical Oncology. Nowotwory. Journal of Oncology. 2018; 68(3): 118–126.
- Jankowski M, Rutkowski A, Zegarski W, et al. The surgical treatment of rectal cancer in Poland. The findings of a multi-center observational study by the Polish Society of Surgical Oncology (PSSO-01). Nowotwory. Journal of Oncology. 2021; 71(5): 282–289.
- Penna M, Hompes R, Arnold S, et al. TaTME Registry Collaborative. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. Ann Surg. 2017; 266(1): 111–117.
- Deijen CL, Velthuis S, Tsai A, et al. COLOR III: A multicentre randomized clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Colorectal Dis. 2016; 18(8): 802–809.
- Lacy AM, Adelsdorfer C, Delgado S, et al. Transanal Total Mesorectal Excision (TaTME): An Updated Perspective. Tech Coloproctol. 2015; 19(9): 505–507.
- Atallah S, Albert M, Monson JR. Critical Review of Transanal Total Mesorectal Excision: Is It Really a Game Changer? Dis Colon Rectum. 2013; 56(6): 115–119.
- Andersen LH, Klein M, Gögenur I, et al. Long-Term Functional Outcome Following Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer. Ann Surg Oncol. 2018; 25(4): 1031–1036.
- Rullier E, Denost Q, Vendrely V, et al. Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum. 2013; 56(5): 560–567.
- Tejedor P, Arredondo J, Simó V, et al. The role of transanal compared to laparoscopic total mesorectal excision (taTME vs. lapTME) for the treatment of mid-low rectal cancer in obese patients: outcomes of a multicenter propensity-matched analysis. Updates Surg. 2023; 75(8): 2191–2200; Erratum in: Updates Surg. 2024; 76(1): 329.
- Li Ze, Liu H, Luo S, et al. Long-term oncological outcomes of transanal versus laparoscopic total mesorectal excision for mid-low rectal cancer: a retrospective analysis of 2502 patients. Int J Surg. 2024; 110(3): 1611–1619.
- Ammann Y, Warschkow R, Schmied B, et al. Is survival after transanal total mesorectal excision (taTME) worse than that after traditional total mesorectal excision? A retrospective propensity score-adjusted cohort study. Int J Colorectal Dis. 2024; 39(1): 28.
- Parnasa SY, Mizrahi I, Helou B, et al. Incidence and Risk Factors for Low Anterior Resection Syndrome following Trans-Anal Total Mesorectal Excision. J Clin Med. 2024; 13(2).